Skip to main content
. 2023 Aug 23;95:104764. doi: 10.1016/j.ebiom.2023.104764

Fig. 1.

Fig. 1

Sensitivity of stHIV-A19 to LEN. (a) Alignment of capsid protein (CA) amino acid sequences for HIV-1 NL4-3, stHIV-A19, and SIVmac239. Locations of known amino acid substitutions conferring LEN resistance are highlighted in yellow. An amino acid difference in the SIVmac239 CA sequence associated with reduced LEN sensitivity for HIV-1 is highlighted in blue. (b) In vitro antiviral dose response curves for LEN against HIV-1 NL4-3, stHIV-A19, or SIVmac239 in multi-round viral replication assays in SupT1-CCR5 cells. Viral RNA content in culture supernatants collected at 7 days post-infection was quantified and expressed as a percentage of vRNA content in no-drug control cultures. Lenacapavir mean EC50 values ± SD determined against each virus are shown. (c) In vitro antiviral dose response curves for LEN against stHIV-A19 in multi-round viral replication assays in primary human and pigtail macaque PBMCs from three independent donors. Viral reverse transcriptase (RT) protein was quantified in culture supernatants collected 7 days post-infection. Calculated EC95 values for LEN against stHIV-A19 in each cell type are shown. Data in (b) and (c) represent means ± SD values from three independent experiments each performed in triplicate.